1577P Early mortality linked to COVID-19 in cancer patients as compared to historical control in pre-pandemic times

Dienstmann, R.; De Marchi, P.; Costa e Silva, M.; Menezes, M.; Cruz, H.; Paes, R.; Alves da Silva, J.; Messias, A. C.; Canedo, J.A.F.; De Melo, A. C.; Reinert, T.; Jacome, A.; Ferreira, B. S.; Mathias, C.; Barrios, C. H.; Ferreira, C. Gil; Ferrari, B. L.

Background: The COVID-19 pandemic remains a public health emergency of global concern, with higher mortality rates in cancer patients as compared to the general population. However, early mortality of COVID19 in cancer patients has not been compared to historical real-world data from oncology population in pre-pandemic times. Methods: Longitudinal multicenter cohort study of patients with cancer and confirmed COVID-19 from Oncoclínicas Group in Brazil from March to December 2020. The primary endpoint was 30-day mortality after isolation of the SARS-CoV-2 by RT-PCR. As historical control, we selected patients from Oncoclínicas Data Lake treated before December 2019 and propensity score-matched to COVID-19 cases (3:1) based on the following clinical characteristics: age, gender, tumor type, disease setting (curative or palliative), time from diagnosis of cancer (or metastatic disease) to COVID-19 infection. Results: In total, 533 cancer patients with COVID-19 were prospectively registered in the database, with median age 60 years, 67% females, most frequent tumor types breast (34%), hematological (16%), gastrointestinal (15%), genitourinary (12%) and respiratory tract malignancies (10%). Most patients were on active systemic therapy or radiotherapy (84%), largely for advanced or metastatic disease (55%). In the overall population, early death rate was 15%, which was numerically higher than the Brazilian general population with COVID-19 diagnosis in 2020 (2.5%). We were able to match 442 cancer patients with COVID-19 to 1,187 controls with cancer from pre-pandemic times. The 30-day mortality rate was 12.4% in COVID-19 cases as compared to 5.4% in pre-pandemic controls with cancer (Odds Ratio 2.49, 95%CI 1.67 - 3.70;P value < 0.01, Power 97.5%). COVID-19 cancer patients had significantly higher death events than historical controls (Hazard Ratio 2.18, 95%CI 1.52 - 3.12;P value < 0.01, Power 99.7%), particularly from 20 to 30 days after diagnosis of the infection. Conclusions: Cancer patients with COVID-19 have an excess mortality 30 days after the infection when compared to matched cancer population from pre-pandemic times and the general population with COVID-19, reinforcing the need for priority vaccination in public health strategies. Legal entity responsible for the study: Oncoclínicas Group. Funding: Amgen. Disclosure: All authors have declared no conflicts of interest.